Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 11.50 GBp
Change Today 0.00 / 0.00%
Volume 2.0M
OXB On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

oxford biomedica plc (OXB) Snapshot

Open
11.75 GBp
Previous Close
11.50 GBp
Day High
11.75 GBp
Day Low
11.50 GBp
52 Week High
03/20/15 - 13.25 GBp
52 Week Low
05/28/14 - 1.93 GBp
Market Cap
295.3M
Average Volume 10 Days
3.8M
EPS TTM
-0.0047 GBp
Shares Outstanding
2.6B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD BIOMEDICA PLC (OXB)

Related News

No related news articles were found.

oxford biomedica plc (OXB) Related Businessweek News

No Related Businessweek News Found

oxford biomedica plc (OXB) Details

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing RetinoStat that has completed Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease and OXB-102 that is in Phase I/II trials preparation for the treatment of Parkinson's disease; and MoNuDin, which is in pre-clinical stage for the treatment of motor neuron disease. In addition, the company is developing TroVax that is in Phase II trial for colorectal cancer, ovarian cancer, and mesothelioma; Anti-5T4 antibody, which is in Phase I trial for the treatment of cancer; and CAR-T 5T4, a combination of LentiVector and 5T4 platform. It has collaborations with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is based in Oxford, the United Kingdom.

134 Employees
Last Reported Date: 04/2/15
Founded in 1995

oxford biomedica plc (OXB) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 429.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 260.0K GBP
Chief Business Officer and Executive Director
Total Annual Compensation: 225.0K GBP
Compensation as of Fiscal Year 2013.

oxford biomedica plc (OXB) Key Developments

Oxford BioMedica PLC Secures $50 Million Loan with Oberland Capital

Oxford BioMedica plc announced that it has secured a $50 million loan facility from a subsidiary of Oberland Capital Healthcare (Oberland Capital). The funds will be used to invest in the Group's capacity expansion to enable it to deliver on commitments under its manufacturing agreement with Novartis and for pipeline advancements and product acquisitions. $25 million of the loan will be drawn down immediately, with the remaining funds available to be drawn down in minimum tranches of $5 million at the Group's option prior to 31 December 2016. The loan is repayable not later than 1 May 2022 and may be prepaid at any time. Over the course of the loan term, interest is payable quarterly at an annual interest rate of 9.5% plus the greater of 1% and three month LIBOR. In addition to interest, a fee is also payable upon any repayment. Oxford BioMedica would also pay an additional amount of 0.35% of annual worldwide net revenues for eight years commencing 1 April 2017 for each $5 million of loan drawn down over $30 million.

Oxford BioMedica Seeks Acquisitions

Oxford BioMedica PLC (LSE:OXB) is seeking acquisitions. Oxford BioMedica secured $50 million loan facility. The funds will be used to invest in capacity expansion, pipeline advancements and product acquisitions.

Oxford BioMedica PLC(LSE:OXB) added to FTSE All-Share Index (GBP)

Oxford BioMedica PLC(LSE:OXB) added to FTSE All-Share Index (GBP)

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 11.50 GBp 0.00

OXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.13 EUR +0.05
Pharming Group NV €0.32 EUR -0.001
Swedish Orphan Biovitrum AB kr135.40 SEK +2.50
Medicines Co/The $25.97 USD -0.32
Veloxis Pharmaceuticals A/S kr0.84 DKK +0.005
View Industry Companies
 

Industry Analysis

OXB

Industry Average

Valuation OXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.4x
Price/Book 12.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit www.oxfordbiomedica.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.